Global Cholera Vaccines Market 2024-2032: Top Key Players - Astellas Pharma Inc., Celldex Therapeutics Inc. (Avant Immunotherapeutics Inc.), Emergent BioSolutions Inc., Eubiologics Co. Ltd., Johnson & Johnson are Leading the Way in Research and Investment

IMARC Group's report titled "Cholera Vaccines Market Report by Vaccine Type (Whole Cell V. Cholerae O1 with Recombinant B-Subunit, Killed Oral O1 and O139), Product (Dukoral, Shanchol, Vaxchora, Euvichol and Euvichol-Plus, and Others), End User (Hospitals and Clinics, Research and Academic Laboratories, and Others), and Region 2024-2032". The global cholera vaccines market size reached US$ 5.4 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 13.0 Million by 2032, exhibiting a growth rate (CAGR) of 10% during 2024-2032.

For an in-depth analysis, you can refer sample copy of the report: https://www.imarcgroup.com/cholera-vaccines-market/requestsample

Factors Affecting the Growth of the Global Cholera Vaccines Industry:

• Growing Incidences of Cholera:

The increasing incidence of cholera worldwide is a significant driver for the cholera vaccines market. Cholera, a highly infectious disease caused by the Vibrio cholerae bacterium, predominantly affects regions with poor sanitation, inadequate clean water supply, and areas affected by natural disasters or humanitarian crises. The World Health Organization (WHO) reports thousands of cholera cases annually, with the potential for outbreaks turning into epidemics in vulnerable areas. This rising prevalence necessitates robust preventive measures, where cholera vaccines play a pivotal role. Countries prone to cholera outbreaks are increasingly integrating cholera vaccination in their public health strategies, thereby propelling market growth. Additionally, global health organizations and governments are collaborating to enhance vaccine accessibility in high-risk areas, further stimulating market expansion.

• Technological Advancements:

Advancements in vaccine technology and increased funding for research and development are key factors driving the cholera vaccines market. Modern biotechnological techniques have enabled the development of more effective and safer vaccines, which provide longer-lasting immunity against cholera. This progress has led to the introduction of oral cholera vaccines (OCVs), which are easier to administer and more suitable for mass vaccination campaigns, especially in resource-limited settings. Additionally, international health agencies, such as Gavi, the Vaccine Alliance, and the WHO, are actively involved in promoting the availability and affordability of cholera vaccines. Their efforts include subsidizing vaccine costs and supporting low-income countries in vaccine procurement, thus making these vaccines more accessible globally. Such initiatives not only address the immediate health concerns but also contribute to long-term disease control and eradication efforts.

• Government Initiatives:

Global health initiatives and preventive strategies form a crucial driver for the cholera vaccines market. International and national health organizations are increasingly focusing on preventive healthcare to combat infectious diseases like cholera. This shift towards prevention rather than treatment has led to a greater emphasis on vaccination programs. Organizations such as the WHO and UNICEF, along with various non-governmental organizations (NGOs), are playing a significant role in raising awareness about cholera and the importance of vaccination, especially in countries with high endemicity. These entities often collaborate to implement large-scale vaccination campaigns, which include cholera vaccines as a key component of their disease control strategy.

Leading Companies Operating in the Global Cholera Vaccines Industry:

• Astellas Pharma Inc.
• Celldex Therapeutics Inc. (Avant Immunotherapeutics Inc.)
• Emergent BioSolutions Inc.
• Eubiologics Co. Ltd.
• Johnson & Johnson
• Merck & Co. Inc.
• Pfizer Inc.
• PharmaChoice Canada Inc.
• Sanofi S.A.
• Takeda Pharmaceutical Company Limited
• Valneva SE

Ask Analyst for Customization and Explore Full Report with TOC & List of Figure: https://www.imarcgroup.com/cholera-vaccines-market

Cholera Vaccines Market Report Segmentation:

By Vaccine Type:

• Whole Cell V. Cholerae O1 with Recombinant B-Subunit
• Killed Oral O1 and O139

Whole cell V. cholerae O1 with recombinant B-subunit represented the largest segment due to the comprehensive protection offered by whole-cell vaccines against cholera.

By Product:

• Dukoral
• Shanchol
• Vaxchora
• Euvichol and Euvichol-Plus
• Others

Dukoral accounted for the largest market share due to the surging awareness regarding the unique formulation of the product, encompassing both cholera and ETEC.

By End Uses:

• Hospitals and Clinics
• Research and Academic Laboratories
• Others

Hospitals and clinics holds the largest market share as they serve as primary access points for medical care.

By Distribution Channel:

Supermarkets and hypermarkets accounted for the largest market share as they cater to a broader customer base.

By Region:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa.

Cholera Vaccines Market Trends:

International organizations, governments, and NGOs are launching immunization initiatives to combat cholera outbreaks in vulnerable regions. These programs aim to increase vaccine accessibility in areas prone to cholera epidemics. Besides, oral cholera vaccines are becoming the preferred choice for cholera prevention due to their ease of administration and efficacy. Manufacturers are focusing on developing improved OCV formulations and expanding their production capacities.

Moreover, governments and health organizations are prioritizing cholera preparedness and response plans. This includes stockpiling cholera vaccines to deploy rapidly in outbreak situations, reducing the impact of cholera epidemics.

Contact Us:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145 | United Kingdom: +44-753-713-2163

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARCs information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the companys expertise.

Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.

This release was published on openPR.